- Home
- PCVX vs RGEN Comparison
PCVX vs RGEN Comparison
Compare PCVX & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCVX
- RGEN
- Stock Information
- Founded
- PCVX 2013
- RGEN 1981
- Country
- PCVX United States
- RGEN United States
- Employees
- PCVX N/A
- RGEN 1783
- Industry
- PCVX Biotechnology: Pharmaceutical Preparations
- RGEN Medical/Dental Instruments
- Sector
- PCVX Health Care
- RGEN Health Care
- Exchange
- PCVX Nasdaq
- RGEN Nasdaq
- Market Cap
- PCVX 12.5B
- RGEN 8.2B
- IPO Year
- PCVX 2020
- RGEN N/A
- Fundamental
- Price
- PCVX $115.14
- RGEN $146.38
- Analyst Decision
- PCVX Strong Buy
- RGEN Buy
- Analyst Count
- PCVX 7
- RGEN 10
- Target Price
- PCVX $139.17
- RGEN $188.38
- AVG Volume (30 Days)
- PCVX 1.2M
- RGEN 871.2K
- Earning Date
- PCVX 11-04-2024
- RGEN 10-29-2024
- Dividend Yield
- PCVX N/A
- RGEN N/A
- EPS Growth
- PCVX N/A
- RGEN N/A
- EPS
- PCVX N/A
- RGEN N/A
- Revenue
- PCVX N/A
- RGEN $602,354,000.00
- Revenue This Year
- PCVX N/A
- RGEN $0.08
- Revenue Next Year
- PCVX N/A
- RGEN $12.97
- P/E Ratio
- PCVX N/A
- RGEN N/A
- Revenue Growth
- PCVX N/A
- RGEN N/A
- 52 Week Low
- PCVX $44.20
- RGEN $110.45
- 52 Week High
- PCVX $119.27
- RGEN $211.13
- Technical
- Relative Strength Index (RSI)
- PCVX 83.97
- RGEN 48.48
- Support Level
- PCVX $77.21
- RGEN $139.41
- Resistance Level
- PCVX $115.44
- RGEN $150.72
- Average True Range (ATR)
- PCVX 3.54
- RGEN 4.97
- MACD
- PCVX 3.86
- RGEN -1.02
- Stochastic Oscillator
- PCVX 83.08
- RGEN 53.59
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
About RGEN Repligen Corporation
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.